Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer ...Middle East

PR Newswire - News
Study results of novel drug-eluting technology highlight potential durability of TAR-200 in patient population with high unmet need CHICAGO, April 30, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from the open-label Phase...

Hence then, the article about janssen reports first results from phase 2 sunrise 1 study of tar 200 and anti pd 1 antibody cetrelimab in patients with bacillus calmette guerin unresponsive non muscle invasive bladder cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News